Immunoglobulin E and T-cell receptor (House dust mite specific) (IgE/TCR (HDM))

This target complex refers to the specific recognition molecules of the adaptive immune system—Immunoglobulin E (IgE) and T-cell receptors (TCRs)—that respond to allergens from the house dust mites Dermatophagoides pteronyssinus and Blomia tropicalis (PubMed: 30243711). IgE antibodies specific to these mites bind to high-affinity FcεRI receptors on mast cells and basophils, creating a sensitized state. Upon subsequent exposure to mite allergens like Der p 1 or Blo t 5, cross-linking of the IgE-FcεRI complex occurs, triggering the immediate release of inflammatory mediators such as histamine and leukotrienes (StatPearls: NBK537020). Simultaneously, TCRs on CD4+ T-helper cells recognize mite-derived peptides presented by MHC class II molecules on antigen-presenting cells. This recognition primarily drives a Th2-polarized cytokine response, involving IL-4, IL-5, and IL-13, which sustains chronic allergic inflammation and eosinophil recruitment (PubMed: 28939340). These interactions are central to the pathogenesis of allergic asthma, rhinitis, and atopic dermatitis, particularly in tropical regions where both mite species are prevalent (World Allergy Organization). Therapeutic interventions target this system either by neutralizing circulating IgE using monoclonal antibodies like Omalizumab to prevent mast cell activation or by modulating the T-cell response through allergen-specific immunotherapy (AIT) to induce immune tolerance (NIH: PMC7119151). AIT promotes the induction of regulatory T cells and the production of IgG4 antibodies that compete with IgE for allergen binding.

Other names

HDM-specific IgEHDM-specific TCRDermatophagoides pteronyssinus allergen receptorsBlomia tropicalis allergen receptorsHouse dust mite specific immune receptors

Omalizumab binds to circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Allergen-specific immunotherapy (AIT) involves the administration of mite allergen extracts to induce T-cell tolerance, shift the immune response from Th2 to Th1/Treg, and stimulate the production of allergen-specific IgG4 blocking antibodies.